{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Salt+Tablets", "query": { "intervention": "Salt Tablets" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 127, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Salt+Tablets&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T17:55:09.924Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00896389", "title": "Salt Loading and Thiazide Intervention Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "Salt loading", "type": "PROCEDURE" }, { "name": "Hydrochlorothiazide (HCTZ)", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 124, "start_date": "2009-10", "completion_date": "2013-03", "has_results": true, "last_update_posted_date": "2022-03-25", "last_synced_at": "2026-09-02T17:55:09.924Z", "location_count": 1, "location_summary": "Lancaster, Pennsylvania", "locations": [ { "city": "Lancaster", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00896389" }, { "nct_id": "NCT05369416", "title": "Renal Metabolism in Salt-sensitive Human Blood Pressure", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "Low sodium diet", "type": "OTHER" }, { "name": "high sodium diet", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "30 Years to 65 Years" }, "enrollment_count": 70, "start_date": "2021-11-01", "completion_date": "2030-01-30", "has_results": false, "last_update_posted_date": "2025-11-13", "last_synced_at": "2026-09-02T17:55:09.924Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05369416" }, { "nct_id": "NCT03893032", "title": "Enhancing Operational Performance in Healthy Rested Soldiers With Pharmacological Stimulants", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cognition" ], "interventions": [ { "name": "Modafinil 200mg", "type": "DRUG" }, { "name": "mixed amphetamine salts", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "United States Army Aeromedical Research Laboratory", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "MALE", "summary": "18 Years to 40 Years · Male only" }, "enrollment_count": 80, "start_date": "2019-07-17", "completion_date": "2019-10", "has_results": false, "last_update_posted_date": "2019-07-31", "last_synced_at": "2026-09-02T17:55:09.924Z", "location_count": 1, "location_summary": "Fort Rucker, Alabama", "locations": [ { "city": "Fort Rucker", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT03893032" }, { "nct_id": "NCT03038620", "title": "Impact of Liraglutide 3.0 on Body Fat Distribution", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Obesity, Visceral", "Cardiovascular Diseases", "Fat Disorder" ], "interventions": [ { "name": "Liraglutide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "35 Years", "maximum_age": null, "sex": "ALL", "summary": "35 Years and older" }, "enrollment_count": 235, "start_date": "2017-01", "completion_date": "2020-10-13", "has_results": true, "last_update_posted_date": "2021-11-19", "last_synced_at": "2026-09-02T17:55:09.924Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03038620" }, { "nct_id": "NCT02799472", "title": "Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "GSK3196165", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "MTX", "type": "DRUG" }, { "name": "Folic (or folinic) acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2016-06-15", "completion_date": "2017-10-30", "has_results": true, "last_update_posted_date": "2021-01-11", "last_synced_at": "2026-09-02T17:55:09.924Z", "location_count": 8, "location_summary": "El Cajon, California • Fort Lauderdale, Florida • Miami, Florida + 5 more", "locations": [ { "city": "El Cajon", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Pinellas Park", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02799472" }, { "nct_id": "NCT02848729", "title": "Drug Interactions Between Morphine and Orally or IV Administered Acetaminophen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pain" ], "interventions": [ { "name": "Oral Acetaminophen", "type": "DRUG" }, { "name": "IV Acetaminophen", "type": "DRUG" }, { "name": "IV Morphine", "type": "DRUG" }, { "name": "Placebo Tablets", "type": "DRUG" }, { "name": "Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mallinckrodt", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 50, "start_date": "2016-02", "completion_date": "2016-03", "has_results": true, "last_update_posted_date": "2020-02-05", "last_synced_at": "2026-09-02T17:55:09.924Z", "location_count": 3, "location_summary": "Tucson, Arizona • Naples, Florida • Kingston, Rhode Island", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Naples", "state": "Florida" }, { "city": "Kingston", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT02848729" }, { "nct_id": "NCT01336634", "title": "Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 177, "start_date": "2011-08-05", "completion_date": "2021-01-07", "has_results": true, "last_update_posted_date": "2022-04-04", "last_synced_at": "2026-09-02T17:55:09.924Z", "location_count": 15, "location_summary": "Los Angeles, California • Orange, California • Aurora, Colorado + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01336634" }, { "nct_id": "NCT03563170", "title": "QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma Non-resectable", "Hepatocellular Carcinoma Recurrent" ], "interventions": [ { "name": "ETBX-011", "type": "BIOLOGICAL" }, { "name": "GI-4000", "type": "BIOLOGICAL" }, { "name": "haNK for infusion", "type": "BIOLOGICAL" }, { "name": "avelumab", "type": "BIOLOGICAL" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "nab-Paclitaxel", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "SBRT", "type": "PROCEDURE" }, { "name": "Aldoxorubicin hydrochloride", "type": "BIOLOGICAL" }, { "name": "ETBX-051", "type": "BIOLOGICAL" }, { "name": "ETBX-061", "type": "BIOLOGICAL" }, { "name": "GI-6207", "type": "BIOLOGICAL" }, { "name": "GI-6301", "type": "BIOLOGICAL" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "N-803", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2018-05-25", "completion_date": "2019-08-23", "has_results": false, "last_update_posted_date": "2021-03-18", "last_synced_at": "2026-09-02T17:55:09.924Z", "location_count": 1, "location_summary": "El Segundo, California", "locations": [ { "city": "El Segundo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03563170" }, { "nct_id": "NCT00059202", "title": "Trial of High-dose Urso in Primary Sclerosing Cholangitis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Primary Sclerosing Cholangitis" ], "interventions": [ { "name": "Ursodeoxycholic Acid", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 150, "start_date": "2002-07", "completion_date": "2008-06", "has_results": true, "last_update_posted_date": "2021-05-03", "last_synced_at": "2026-09-02T17:55:09.924Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00059202" }, { "nct_id": "NCT01074294", "title": "Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Attention Deficit Hyperactivity Disorder" ], "interventions": [ { "name": "OPDC-34712", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Stimulant Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 740, "start_date": "2010-03-16", "completion_date": "2011-06-20", "has_results": true, "last_update_posted_date": "2023-02-02", "last_synced_at": "2026-09-02T17:55:09.924Z", "location_count": 35, "location_summary": "Little Rock, Arkansas • Beverly Hills, California • Irvine, California + 32 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01074294" } ] }